Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.

Для цитирования: Chen Zhiwei, Yang Fang, Jiang Zhou, Sun Longhua, Wu Lin, Han Zhengxiang, Fan Yun, Zhao Yanqiu, Li Xingya, Xu Haipeng, Meng Xiangjiao, Liu Ying, Zhang Zhiye, Luo Hui, Ma Xuelei, Ma Xuezhen, Shi Qin, Zhang Zhongmin, Yang Runxiang, Wang Pingli, Pan Pinhua, Ai Xiaohong, Li Jie, Pu Xingxiang, Wang Zhiwu, Fang Jian, He Ming, He Yong, Guo Shuliang, Li Juan, Wang Hongbiao, Zhang Junqiang, Chu Qian, Liu Xuewen, Ying Shenpeng, Wu Hongcheng, Sun Hongmei, Ji Yinghua, Zhou Ming, Cao Chao, Tang Kejing, Li Zhengguo, Li Dairong, Zhang Zhihong, Li Jie, Zhou Jianya, Yang Hongzhong, Du Yingying, Yang Hui, Shi Jian, Chen Hualin, Moore Amy C, Lu Shun. Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.. Future oncology (London, England). 2026. DOI: 10.1080/14796694.2026.2676052.